Small cell lung cancer. Complete remission and improved survival

Area of Science:

• Oncology
• Pulmonology
• Radiotherapy
• Medical Oncology

Background:

• Small cell lung cancer (SCLC) is an aggressive form of lung cancer with limited treatment options for limited-stage disease.
• Achieving complete remission is a critical step towards improving survival outcomes in SCLC patients.
• Combined modality treatments are being explored to enhance therapeutic efficacy in limited-stage SCLC.

Purpose of the Study:

• To evaluate the efficacy of combined supervoltage radiotherapy and a specific chemotherapy regimen in patients with limited-stage small cell lung cancer.
• To assess the rate of complete remission, survival, and relapse-free survival in patients treated with this combined modality approach.
• To identify the primary toxicities associated with the combined treatment regimen.

Main Methods:

• Thirty-two patients diagnosed with limited-stage small cell lung cancer were enrolled in the study.
• Patients received a treatment protocol involving supervoltage radiotherapy concurrently with a combination chemotherapy regimen (cyclophosphamide, doxorubicin, vincristine).
• Fiberoptic bronchoscopy was utilized to confirm the status of complete remission.

Main Results:

• A high rate of complete remission was observed, with 26 out of 27 completely re-evaluated patients achieving this status.
• Seventeen out of 32 patients remain alive at follow-up, with a median survival of 16+ months (range 8+ to 28+ months).
• Ten patients are alive and relapse-free, with a median of 19+ months (range 12+ to 28+ months). Transient granulocytopenia was the most significant toxicity.

Conclusions:

• The combined supervoltage radiotherapy and chemotherapy regimen is effective in achieving complete remission, symptomatic improvement, and improved survival in the majority of patients with limited-stage small cell lung cancer.
• This therapeutic approach demonstrates potential for disease eradication in a subset of patients.
• The findings support the use of this combined modality treatment as a viable option for limited-stage SCLC.